Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-infective formulation and methods of use

A preparation, mammary gland technology, applied in the direction of anti-infective drugs, topical antibacterial agents, pharmaceutical formulations, etc., can solve problems such as impact, animal injury, infection of mammary glands, etc.

Inactive Publication Date: 2011-08-17
BAYER NEW ZELAND LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0026] The disadvantage of the sealing method is that microorganisms already present in the teat will be sealed inside and can infect the mammary gland without any hindrance
Additionally, this natural sealing process may also be affected, slowed down or otherwise altered, which may cause harm to the animal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-infective formulation and methods of use
  • Anti-infective formulation and methods of use
  • Anti-infective formulation and methods of use

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0132] Example 1: Formulation and production - no thickener

[0133] The following table is an overview of the embodiments of the formulation

[0134] Table 1 - Formulation Overview

[0135]

[0136] As described in Table 1, the key difference between Formulation 1 and Formulation 2 is the amount of chlorhexidine (CHX) added.

[0137] Below is the manufacturing process of producing above-mentioned preparation:

[0138] 1. Take heavy liquid paraffin and aluminum stearate (aluminum stearate);

[0139] 2. Add aluminum stearate to the liquid paraffin, then stir until a smooth suspension without lumps;

[0140] 3. Heat the mixture obtained in step 2 until the temperature rises to 150°C;

[0141] 4. Keep at 150°C for 1 hour (sterilization);

[0142] 5. Cool the mixture obtained in step 4 to below 40°C, and stir until a smooth matrix is ​​formed;

[0143] 6. Weigh and add chlorhexidine, stir and mix until uniform, to ensure that chlorhexidine is evenly dispersed in the matri...

example 2

[0147] Example 2: Formulation and production - including thickeners and preservatives

[0148] Table 2 describes preferred formulations containing thickeners and preservatives.

[0149] Table 2 Formulations Containing Thickeners and Preservatives

[0150]

[0151] Below is the manufacturing process of producing above-mentioned preparation:

[0152] 1. Take heavy liquid paraffin barium sulfate, aluminum stearate, oxygen phase silicon dioxide 200 (Aerosol200), methylparaben and propylparaben;

[0153] 2. Heat the liquid paraffin to 80°C. Keeping at this temperature, add barium sulfate, aluminum stearate, oxysilica 200, methyl p-hydroxybenzoate and propyl p-hydroxybenzoate to the liquid paraffin and stir; continue stirring until a smooth suspension is formed;

[0154] 3. Heat the mixture obtained in step 2 until the temperature rises to 150°C;

[0155] 4. Keep this temperature in a container with a lid for 2 hours without stirring;

[0156] 5. Cool the mixture obtained in...

example 3

[0161] Example 3: Bacterial Challenge Test Results for Barium Sealants

[0162] The purpose of this experiment was to predict the optimal concentration of a biocide in a formulation that would form a chemical barrier against bacteria proliferating through the teat ducts.

[0163] Another objective was to conduct a detailed study of the factors affecting the release rate of the fungicide, including drug concentration, chemical form (salt or base) and formulation.

[0164] Chlorhexidine at higher concentrations (greater than 100 μg / ml) is bactericidal against most bacteria. Chlorhexidine at lower concentrations (1-100 μg / ml) is used as a bacteriostatic agent (European Medicines Agency).

[0165] Ideally, the formulation should contain chlorhexidine in an amount such that it has a bactericidal concentration after application to the teat ducts and / or the lower part of the teat cisterns. Excessive concentrations should be avoided as high concentrations can cause tissue inflammati...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a formulation for administration to the teat canal or / and lower portion of teat cistern of a mammary gland of an animal, wherein the formulation prior to delivery is in the form of a paste, the formulation including: an oil-based physical barrier material which is able to form a cohesive mass in the teat canal and / or the lower portion of the teat cistern, and at least one antiseptic compound mixed with the barrier material.

Description

technical field [0001] The present invention relates to an anti-infective preparation and its use method, more specifically, the present invention relates to an anti-infection preparation for preventing or treating mammary gland infection and its use method. Background technique [0002] The high incidence of bovine mastitis is one of the major problems associated with dairy cows, especially at or near the end of the dry period, when cows are particularly susceptible to mastitis. The issue is equally applicable to other mammals, but this discussion is primarily in reference to bovine mastitis. [0003] The main pathogens associated with dry mastitis infection may include Staphylococcus aureus, Streptococcus uberis, and Streptococcus dysgalactiae. [0004] A variety of treatments have also been used to suppress the occurrence of mastitis including DCT (Dry Cow Therapy), external and internal teat closures. However, as detailed below, all existing therapeutic products have s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K33/24A61K9/00A61K31/155A61P31/02
CPCA61K31/155A61K9/0041A61K9/06A61K33/00A61P31/00A61P31/02A61K2300/00
Inventor 伊恩·乔治·塔克吴紫梅法迪勒·阿拉维韦恩·弗雷德里克·利奇
Owner BAYER NEW ZELAND LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com